News from abbvie A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

02 Aug, 2019, 13:45 BST AbbVie's MAVIRET™ (glecaprevir/pibrentasvir) Approved by European Commission to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Commission has granted marketing...


28 Jul, 2017, 16:03 BST European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the European Commission has granted marketing authorization for...


23 Jun, 2017, 12:36 BST AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of...


23 Jun, 2017, 07:30 BST AbbVie Announces Pivotal Phase 2 Trial Evaluating VENCLYXTO™ (venetoclax) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion to be Presented at 22nd European Hematology Association (EHA) Annual Congress

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the presentation of results from the pivotal Phase 2 study of VENCLYXTO™...


14 Jun, 2017, 23:01 BST AbbVie Presents Real-World Data Evaluating the Relationship between Participation in a Patient Support Program and Outcomes in Patients with Moderate to Severe Rheumatoid Arthritis

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today presented results from a 78-week post-marketing observational study showing that...


12 Jun, 2017, 07:00 BST AbbVie Announces New Data Evaluating Venetoclax in a Variety of Hematologic Malignancies at the 22nd European Hematology Association Congress

AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that data from multiple clinical trials evaluating venetoclax, a...


27 Jan, 2017, 12:48 GMT AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results

- Reports Full-Year Diluted EPS of $3.63 on a GAAP Basis; Adjusted Diluted EPS of $4.82, Reflecting Growth of 12.4 Percent - Delivers Full-Year Net...


08 Dec, 2016, 06:00 GMT European Commission Grants Conditional Marketing Approval for AbbVie's VENCLYXTO™ (venetoclax) Monotherapy for Appropriate Patients with Difficult-To-Treat Chronic Lymphocytic Leukaemia

- VENCLYXTO™ (venetoclax) monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53...


02 Nov, 2016, 12:53 GMT AbbVie Announces European Fixed Income Investor Meetings

AbbVie (NYSE: ABBV) today announced that it has mandated Barclays, BofA Merrill Lynch, Deutsche Bank, J.P. Morgan and Morgan Stanley (Global...


14 Oct, 2016, 12:26 BST AbbVie Receives CHMP Positive Opinion for VENCLYXTO™ (venetoclax) Tablets for Appropriate Patients with Difficult-To-Treat Chronic Lymphocytic Leukaemia

- CHMP recommends VENCLYXTO monotherapy for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in...


26 Feb, 2016, 14:52 GMT AbbVie Receives CHMP Positive Opinion for VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Without Ribavirin for the Treatment of Chronic Hepatitis C in Genotype 1b Patients with Compensated Cirrhosis (Child-Pugh A) in Europe

AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of...


26 Feb, 2016, 11:00 GMT AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)

AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced the European Medicines Agency (EMA) has granted Orphan Drug Designation to...


28 Jan, 2016, 05:59 GMT Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy

AbbVie (NYSE:ABBV), a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy ...


20 Jan, 2016, 13:30 GMT AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

AbbVie (NYSE:ABBV), a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy ...


06 Dec, 2015, 17:00 GMT AbbVie Announces New England Journal of Medicine Online Publication of Venetoclax Phase 1 Data in Relapsed/Refractory Chronic Lymphocytic Leukemia

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the online publication of new data in the New England Journal of Medicine...


06 Dec, 2015, 16:05 GMT AbbVie Reports Phase 2 Results of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced results of a Phase 2, open label trial studying investigational compound...


16 Nov, 2015, 14:00 GMT AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced data from the SURVEYOR studies of its investigational HCV regimen, ABT-493,...


14 Nov, 2015, 14:01 GMT AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data from its ongoing Phase 3b TOPAZ-II study evaluating VIEKIRA PAK®...


30 Oct, 2015, 10:55 GMT AbbVie Reports Third-Quarter 2015 Financial Results

- Reports Third-Quarter Adjusted EPS of $1.13, Up Nearly 27 Percent and Exceeding Previous Guidance Range of $1.04 to $1.06; Reports GAAP EPS of...


30 Oct, 2015, 10:54 GMT AbbVie Outlines Long-Term Strategic and Financial Objectives; Company Positioned for Strong Performance

- Company Expects to Deliver Double-Digit Adjusted Earnings-Per-Share (EPS) Growth on Average Through 2020 - Guides to Total Company Sales of...


08 Oct, 2015, 07:00 BST Real Stories, Real Voices Break the Silence Around a Painful, Chronic Skin Disease

AbbVie, a global biopharmaceutical company, today is launching Voices of HS, a new global campaign to increase awareness and support for people who...


05 Oct, 2015, 14:00 BST AbbVie Demonstrates Leadership in Dermatology with 26 Abstracts at the European Academy of Dermatology and Venereology Congress

AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that 26 abstracts on HUMIRA® (adalimumab) and hidradenitis suppurativa (HS), ...


01 Oct, 2015, 18:24 BST AbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) and Ongoing Clinical Development Program at The Liver Meeting® 2015

AbbVie (NYSE: ABBV), a global research-based biopharmaceutical company, today announced that 34 abstracts from its chronic hepatitis C clinical...


28 Sep, 2015, 07:00 BST AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C

- New interferon and ribavirin-free treatment option for patients with most common type of hepatitis in Japan, genotype 1 chronic hepatitis C,...


25 Sep, 2015, 12:22 BST AbbVie to Advance Once-Daily ABT-494 to Phase 3 in Rheumatoid Arthritis by Year-End

AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational...